Editorial

You have full text access to this OnlineOpen article

Perioperative chemotherapy for urothelial cancer†

How have we made a “sow's ear” out of a chemotherapy-sensitive tumor?

  1. Tanya B. Dorff MD,
  2. David I. Quinn MBBS, PhD‡,*

Article first published online: 30 JUL 2009

DOI: 10.1002/cncr.24569

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5139–5142, 15 November 2009

Additional Information

How to Cite

Dorff, T. B. and Quinn, D. I. (2009), Perioperative chemotherapy for urothelial cancer. Cancer, 115: 5139–5142. doi: 10.1002/cncr.24569

Author Information

  1. Division of Oncology, University of Southern California, Los Angeles, California

  1. ‡

    Fax: (323) 865-0061

*Kenneth J. Norris Jr. Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Suite 3453, Los Angeles, CA 90033

  1. †

    See referenced Original Article on pages 5193–201, this issue.

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 30 JUL 2009
  3. Manuscript Accepted: 6 FEB 2009
  4. Manuscript Received: 3 FEB 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (81K)

References

  • 1
    Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976; 294: 405-410.
  • 2
    Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988; 80: 30-36.
  • 3
    Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer. N Engl J Med. 2004; 350: 351-360.
  • 4
    von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068-3077.
  • 5
    Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer. 2003; 97( 8 suppl): 2115-2119.
    Direct Link:
  • 6
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866.
  • 7
    Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004; 172: 481-484.
  • 8
    Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004; 22: 2781-2789.
  • 9
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003; 361: 1927-1934.
  • 10
    Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004; 171( 2 pt 1): 561-569.
  • 11
    Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of 2 Nordic studies. Eur Urol. 2004; 45: 297-303.
  • 12
    Quek ML, Nichols PW, Yamzon J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the University of Southern California experience. J Urol. 2005; 174: 93-96.
  • 13
    Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19: 4005-4013.
  • 14
    Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007; 25: 3456-3461.
  • 15
    Gallagher DJ, Milowsky MI, Iasonos A, et al. Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer. 2009; 115: 5193-5201.
    Direct Link:
  • 16
    Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006; 42: 50-54.
  • 17
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001; 19: 666-675.
  • 18
    Cote RJ, Klotz LH. Combination Chemotherapy in Treating Patients With Bladder Cancer: NCT00005047; SWOG-4B951, LAC-USC-4B951, NCI-G00-1715. Available at: http://clinicaltrials.gov/ct2/show/NCT00005047. Accessed January 2, 2009.
  • 19
    Goebell PJ, Groshen S, Schmitz-Drager BJ, et al. Concepts for banking tissue in urologic oncology—the International Bladder Cancer Bank. Clin Cancer Res. 2005; 11( 2 pt 1): 413-415.
  • 20
    Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004; 22: 1007-1013.
  • 21
    Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007; 18: 522-528.
View Full Article (HTML) Get PDF (81K)